Pharma outlook in the MENA region: an insider's view

mena_li

While drugmakers tend to gravitate towards the mature markets, they’re also naturally keen to identify investment opportunities elsewhere. After all, sales outside of the EU, USA and Japan account for about 20% of the global pharmaceuticals market.

After the turn of the century, the BRICS region - comprising Brazil, Russia, India, China, and later South Africa - was heralded as the future engine of growth.

Investment in the BRICS continues, but the honorific has lost some of its shine.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical